{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:27:25Z","timestamp":1707524845777},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.7759\/cureus.33190","type":"journal-article","created":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T01:29:31Z","timestamp":1672536571000},"source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 Infection in Winter 2021\/2022: The Association of Varying Clinical Manifestations With and Without Prior Vaccination"],"prefix":"10.7759","author":[{"given":"Menachem","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avrohom","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Alessandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Glatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Zyskind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Enhancing response to Omicron SARS-CoV-2 variant. technical brief and priority actions for member states. (2022). Accessed: August 8, 2022: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/2022-01-07-global-technical-brief-and-priority-action-on-omicron...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7050e1","article-title":"SARS-CoV-2 B.1.1.529 (Omicron) variant - United States, December 1-8, 2021","volume":"70","author":"CDC COVID-19 Response Team","year":"2021","unstructured":"CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) variant - United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:1731-4. 10.15585\/mmwr.mm7050e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","unstructured":"Centers for Disease Control and Prevention. COVID data tracker. Accessed: August 12, 2022: https:\/\/covid.cdc.gov\/covid-data-tracker\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27516","article-title":"Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa","volume":"94","author":"Wang L\ufeff","year":"2022","unstructured":"Wang L\ufeff, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J Med Virol. 2022, 94:1728-33. 10.1002\/jmv.27516","journal-title":"J Med Virol"},{"key":"ref5","unstructured":"GISAID. tracking of hCoV-19 variants. Accessed: August 12, 2022: https:\/\/gisaid.org\/hcov19-variants\/."},{"key":"ref6","unstructured":"National Institute for Communicable Diseases. COVID-19 weekly epidemiology brief. (2021). https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2021\/12\/COVID-19-Weekly-Epidemiology-Brief-week-47-2021.pdf."},{"key":"ref7","unstructured":"UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. (2021). Accessed: August 12, 2022: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1043807\/technical-bri...."},{"key":"ref8","unstructured":"European Centre for Disease Prevention and Control. implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU\/EEA - first update. (2021). https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/threat-assessment-covid-19-emergence-sars-cov-2-variant-omic...."},{"key":"ref9","unstructured":"Centers for Disease Control and Prevention. potential rapid increase of Omicron variant infections in the United States. (2021). Accessed: August 12, 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/forecasting\/mathematical-modeling-outbreak.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"Lipsitch M","year":"2022","unstructured":"Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022, 22:57-65. 10.1038\/s41577-021-00662-4","journal-title":"Nat Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021, 397:99-111. 10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, et al.. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021, 384:403-16. 10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal J","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, et al.. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021, 373:n1088. 10.1136\/bmj.n1088","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study","volume":"397","author":"Hall VJ","year":"2021","unstructured":"Hall VJ, Foulkes S, Saei A, et al.. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021, 397:1725-35. 10.1016\/S0140-6736(21)00790-X","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021","volume":"70","author":"Thompson MG","year":"2021","unstructured":"Thompson MG, Burgess JL, Naleway AL, et al.. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:495-500. 10.15585\/mmwr.mm7013e3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan N","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, et al.. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021, 384:1412-23. 10.1056\/NEJMoa2101765","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels KB","year":"2021","unstructured":"Pouwels KB, Pritchard E, Matthews PC, et al.. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021, 27:2127-35. 10.1038\/s41591-021-01548-7","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews N","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, et al.. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022, 386:340-50. 10.1056\/NEJMoa2115481","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad LJ","year":"2021","unstructured":"Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021, 385:187-9. 10.1056\/NEJMc2104974","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews N","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, et al.. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022, 386:1532-46. 10.1056\/NEJMoa2119451","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16634","article-title":"Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-March 2021","volume":"21","author":"Teran RA","year":"2021","unstructured":"Teran RA, Walblay KA, Shane EL, et al.. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-March 2021. Am J Transplant. 2021, 21:2290-7. 10.1111\/ajt.16634","journal-title":"Am J Transplant"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1095959","article-title":"What's the evidence for COVID-19 booster shots?","volume":"193","author":"Vogel L","year":"2021","unstructured":"Vogel L, Duong D. What's the evidence for COVID-19 booster shots?. CMAJ. 2021, 193:E1400-1. 10.1503\/cmaj.1095959","journal-title":"CMAJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi EK","year":"2022","unstructured":"Accorsi EK, Britton A, Fleming-Dutra KE, et al.. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022, 327:639-51. 10.1001\/jama.2022.0470","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00056-3","article-title":"Omicron severity: milder but not mild","volume":"399","author":"Nealon J","year":"2022","unstructured":"Nealon J, Cowling BJ. Omicron severity: milder but not mild. Lancet. 2022, 399:412-3. 10.1016\/S0140-6736(22)00056-3","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.046","article-title":"Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study","volume":"9","author":"Silverberg JI","year":"2021","unstructured":"Silverberg JI, Zyskind I, Naiditch H, et al.. Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study. J Allergy Clin Immunol Pract. 2021, 9:3331-8. 10.1016\/j.jaip.2021.06.046","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2014.12.011","article-title":"Latent class analysis reveals distinct subgroups of patients based on symptom occurrence and demographic and clinical characteristics","volume":"50","author":"Miaskowski C","year":"2015","unstructured":"Miaskowski C, Dunn L, Ritchie C, et al.. Latent class analysis reveals distinct subgroups of patients based on symptom occurrence and demographic and clinical characteristics. J Pain Symptom Manage. 2015, 50:28-37. 10.1016\/j.jpainsymman.2014.12.011","journal-title":"J Pain Symptom Manage"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/121068-sars-cov-2-infection-in-winter-20212022-the-association-of-varying-clinical-manifestations-with-and-without-prior-vaccination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:22Z","timestamp":1707508042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/121068-sars-cov-2-infection-in-winter-20212022-the-association-of-varying-clinical-manifestations-with-and-without-prior-vaccination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.33190","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,31]]}}}